Vaccine immunopotentiators of the future (Q36959938)

17 August 2017

1 reference

title

Vaccine immunopotentiators of the future (English)

1 reference

17 August 2017

Schijns VE

1

1 reference

PubMed ID

17914440

17 August 2017

Degen WG

series ordinal

2

1 reference

PubMed ID

17914440

17 August 2017

language of work or name

English

0 references

publication date

3 October 2007

1 reference

Clinical Pharmacology & Therapeutics

17 August 2017

1 reference

17 August 2017

82

1 reference

17 August 2017

6

1 reference

17 August 2017

750-755

1 reference

Approaching the asymptote? Evolution and revolution in immunology

17 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

Tolerance, danger, and the extended family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

The immune system evolved to discriminate infectious nonself from noninfectious self

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Type 1 and type 2 responses to Leishmania major

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

A healthier climate for the funding of vaccine research

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Immunological concepts of vaccine adjuvant activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Antigenicity of Soluble Protein in the Presence of High Levels of Antibody : a Possible Mode of Action of the Antigen Adjuvants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

The relevance of cytokines for development of protective immunity and rational design of vaccines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Recent advances in the discovery and delivery of vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

1 reference

7 January 2021

The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

CTLA-4 blockade: autoimmunity as treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100394

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100394

1 reference

17 August 2017

1 reference

PubMed ID

17914440